TLR Agonists as Adjuvants for Cancer Vaccines
TLR Agonists as Adjuvants for Cancer Vaccines
复制标题
DOI：
10.1007/978-981-10-5987-2_9
复制
发表时间：
2017-01-01
期刊：
影响因子：
--
通讯作者：
Jenkins, Brendan
中科院分区：
文献类型：
--
作者：
Li, Ji-Kun;Balic, Jesse J.;Jenkins, Brendan
Toll-like receptors (TLRs) are one of the best characterised families of pattern recognition receptors (PRRs) and play a critical role in the host defence to infection. Accumulating evidence indicates that TLRs also participate in maintaining tissue homeostasis by controlling inflammation and tissue repair, as well as promoting antitumour effects via activation and modulation of adaptive immune responses. TLR agonists have successfully been exploited to ameliorate the efficacy of various cancer therapies. In this chapter, we will discuss the rationales of using TLR agonists as adjuvants to cancer treatments and summarise the recent findings of preclinical and clinical studies of TLR agonist-based cancer therapies.
